DPI-289

a mixed delta opioid agonist-mu opioid antagonist (DAMA) for the treatment of Parkinson disease

Also Known As:

4-((alpha-R)-alpha-((2S,5R)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Dyskinesias (Dyskinesia) 01/01/2018 - "However, the combination of LDl and DPI-289 reduced parkinsonism for 6 h (duration of monitoring), with parkinsonism being reduced by 35% and activity increased by 90% but with no increase in dyskinesia over that observed with LDl alone. " 01/01/2018 - "The combination of DPI-289 (20 mg/kg) and a low-dose of L-DOPA (LDl) provided anti-parkinsonian benefits greater than LDl alone without eliciting any significant dyskinesia. "
2.	Parkinsonian Disorders (Parkinsonism) 01/01/2018 - "In fact, over the 6 h period of observation, DPI-289 (20 mg/kg) decreased parkinsonism by 19% and increased activity by 67% compared to vehicle treatment. " 01/01/2018 - "However, the combination of LDl and DPI-289 reduced parkinsonism for 6 h (duration of monitoring), with parkinsonism being reduced by 35% and activity increased by 90% but with no increase in dyskinesia over that observed with LDl alone. "
3.	Parkinson Disease (Parkinson's Disease) 01/01/2018 - "Thus, DPI-289 has potential to improve the benefits of dopaminergic therapy in Parkinson's disease." 01/01/2018 - "DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease."

1.	Narcotic Antagonists (Opioid Antagonists)
2.	Levodopa (L Dopa)
3.	Opioid Analgesics (Opioids)
4.	oxidized low density lipoprotein

1.	Therapeutics